{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rapamycin&page=19", "query": { "intervention": "rapamycin", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 647, "total_pages": 65, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rapamycin&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rapamycin&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T15:24:45.247Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03578432", "title": "Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Salivary Gland Dysfunction", "Xerostomia", "Head and Neck Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 2, "start_date": "2018-05-04", "completion_date": "2019-11-15", "has_results": false, "last_update_posted_date": "2019-12-02", "last_synced_at": "2026-10-19T15:24:45.247Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03578432" }, { "nct_id": "NCT05105152", "title": "PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Refractory", "Acute Myeloid Leukemia, in Relapse" ], "interventions": [ { "name": "SC-DARIC33", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 18, "start_date": "2021-11-29", "completion_date": "2041-01-31", "has_results": false, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-10-19T15:24:45.247Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05105152" }, { "nct_id": "NCT00060645", "title": "Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors", "Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "ridaforolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2003-05", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2015-08-27", "last_synced_at": "2026-10-19T15:24:45.247Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060645" }, { "nct_id": "NCT04203901", "title": "Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Renal Cell Carcinoma" ], "interventions": [ { "name": "CMN-001", "type": "BIOLOGICAL" }, { "name": "Nivolumab+Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib+Everolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "CoImmune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2020-07-22", "completion_date": "2023-09-28", "has_results": false, "last_update_posted_date": "2023-10-02", "last_synced_at": "2026-10-19T15:24:45.247Z", "location_count": 9, "location_summary": "Tampa, Florida • Atlanta, Georgia • Rochester, Minnesota + 5 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Syracuse", "state": "New York" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04203901" }, { "nct_id": "NCT03660930", "title": "Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Soft Tissue Sarcoma", "Locally Advanced Soft Tissue Sarcoma", "Metastatic Soft Tissue Sarcoma" ], "interventions": [ { "name": "Sirolimus Albumin-bound Nanoparticles", "type": "DRUG" }, { "name": "Pazopanib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2019-04-01", "completion_date": "2024-07-31", "has_results": true, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-10-19T15:24:45.247Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03660930" }, { "nct_id": "NCT01935128", "title": "Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Transplant" ], "interventions": [ { "name": "Arm 1 Everolimus/Reduced dose tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Toledo Health Science Campus", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2013-07-03", "completion_date": "2020-07", "has_results": true, "last_update_posted_date": "2022-05-26", "last_synced_at": "2026-10-19T15:24:45.247Z", "location_count": 1, "location_summary": "Toledo, Ohio", "locations": [ { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01935128" }, { "nct_id": "NCT02105766", "title": "Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease", "Thalassemia", "Stem Cell Transplantation", "Graft vs Host Disease" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Pentostatin", "type": "DRUG" }, { "name": "Radiotherapy", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "4 Years to 80 Years" }, "enrollment_count": 56, "start_date": "2014-04-21", "completion_date": "2027-12-31", "has_results": true, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-19T15:24:45.247Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02105766" }, { "nct_id": "NCT01536054", "title": "Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Fallopian Tube Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Primary Peritoneal Cavity Cancer", "Stage IIA Fallopian Tube Cancer", "Stage IIA Ovarian Epithelial Cancer", "Stage IIA Primary Peritoneal Cavity Cancer", "Stage IIB Fallopian Tube Cancer", "Stage IIB Ovarian Epithelial Cancer", "Stage IIB Primary Peritoneal Cavity Cancer", "Stage IIC Fallopian Tube Cancer", "Stage IIC Ovarian Epithelial Cancer", "Stage IIC Primary Peritoneal Cavity Cancer", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Epithelial Cancer", "Stage IIIA Primary Peritoneal Cavity Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Epithelial Cancer", "Stage IIIB Primary Peritoneal Cavity Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Epithelial Cancer", "Stage IIIC Primary Peritoneal Cavity Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 7, "start_date": "2012-08-20", "completion_date": "2015-04-21", "has_results": false, "last_update_posted_date": "2020-03-27", "last_synced_at": "2026-10-19T15:24:45.247Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01536054" }, { "nct_id": "NCT01633060", "title": "A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" }, { "name": "BKM120 matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 432, "start_date": "2012-10-03", "completion_date": "2017-09-21", "has_results": true, "last_update_posted_date": "2019-01-30", "last_synced_at": "2026-10-19T15:24:45.247Z", "location_count": 37, "location_summary": "Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 24 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01633060" }, { "nct_id": "NCT01853423", "title": "Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Facial Angiofibroma" ], "interventions": [ { "name": "Rapamune", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Le Bonheur Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "3 Years to 45 Years" }, "enrollment_count": 11, "start_date": "2013-10", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-08-19", "last_synced_at": "2026-10-19T15:24:45.247Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01853423" } ] }